A bivalent molecular glue linking lysine acetyltransferases to oncogene-induced cell death

Meredith N Nix1, Sai Gourisankar2, Kevin J Bowman3

  • 1Department of Chemical and Systems Biology, Stanford University, Stanford, CA, USA; Department of Chemistry, Stanford University, Stanford, CA, USA.

Cell
|July 20, 2026
PubMed

Insights

Scientists developed novel small-molecule therapies called KAT-TCIPs to target diffuse large B cell lymphoma. These therapies reprogram the epigenome, activating cell death pathways and offering a new approach for cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Chemical Biology

Background:

  • Developing targeted cancer therapies that induce specific cancer cell death is crucial for preventing relapse.
  • Diffuse large B cell lymphoma (DLBCL) is the most common form of non-Hodgkin lymphoma, necessitating effective treatment strategies.

Purpose of the Study:

  • To provide the mechanistic basis for a small-molecule approach using chemically induced proximity (CIP) to kill DLBCL cells.
  • To develop novel transcriptional/epigenetic chemical inducers of proximity (TCIPs) that leverage lysine acetyltransferase (KAT) activity.

Main Methods:

  • Development of KAT-based TCIPs (KAT-TCIPs) designed to redirect p300/CREB-binding protein (CBP) activity.
  • Utilizing the crystal structure of the chemically induced p300-BCL6 complex to understand potency and selectivity.
  • Investigating the genomic responses of TCIPs recruiting different transcriptional activators (p300, BRD4, CDK9).

Main Results:

  • The lead KAT-TCIP reprograms the epigenome to initiate apoptosis in DLBCL cells.
  • The study revealed how protein-protein interactions can be exploited for therapeutic effect.
  • Distinct genomic responses were observed based on the recruited transcriptional activator, suggesting specialized therapeutic applications.

Conclusions:

  • Oncogenic drivers can be co-opted to activate robust cell death pathways.
  • KAT-TCIPs represent a promising small-molecule strategy for targeting DLBCL by inducing specific cancer cell death.
  • The mechanism provides a foundation for developing tailored TCIP-based therapies for various cancers.

Related Concept Videos

Covalently Linked Protein Regulators02:04

Covalently Linked Protein Regulators

Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein.
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Anaphase Promoting Complex00:50

Anaphase Promoting Complex

The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...